# A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

> **NCT06340581** · PHASE1 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A: BGF MDI HFA
- **DRUG:** Treatment B: BGF MDI HFO
- **DRUG:** Treatment C: BGF MDI HFO
- **DEVICE:** AeroChamber Plus Flow-Vu Spacer

## Key facts

- **NCT ID:** NCT06340581
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10-17
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study no longer required.
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06340581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06340581, "A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06340581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*